《新股表現》微創機器人(02252.HK)收45.8元高上市價6% 每手賬面賺1,300元
上海微創機器人-B(02252.HK)首日掛牌,股價低開7.9%報39.8元,最低見39.6元獲承接,掉頭回升,午後初段曾倒升逾14%高見49.4元遇壓,全日收45.8元,較上市價43.2元,反覆高2.6元或6%,成交2,182萬股,涉資9.6億元。不計手續費,每手500股,賬面賺1,300元。
由微創醫療(00853.HK)分拆上市的微創機器人是全球第一梯隊手術機器人公司,其致力於設計、開發及商業化手術機器人,以協助外科醫生完成複雜外科手術。根據弗若斯特沙利文資料,微創醫療機器人是全球行業中唯一一家擁有覆蓋五大主要和快速增長的手術專科(即腔鏡、骨科、泛血管、經自然腔道及經皮穿刺手術)產品組合公司。是次上市共發售3,620萬股H股,並已引入包括私募投資基金Aspex、Hillhouse Funds及LAV等七家基石投資者,合共認購1,629萬股H股。至於10%公開發售獲近163倍超購,已啓動回撥機制佔比增至50%,認購一手中籤率僅3.3%;股份以招股範圍(36-43.2)上限定價,料集資淨額約14.57億元,主要用於核心產品圖邁、骨科手術機器人和其他候選產品,通過引進授權、收購、股權投資或組合營方式取得創新的機器人技術及產品擴張微創醫療機器人產品組合等。上市聯席保薦人分別摩通及中金。
微創機器人執行董事兼總裁何超於網上會議指,手術機器人於國外是重要醫療發展方向,目前在各個領域都廣泛應用,而內地市場滲透嚴重不足,故未來發展空間龐大,預期今年底至明年集團將有數款產品可能獲批上市,取得註冊批準後將加快推進大規模商用及臨牀應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.